<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00104897</url>
  </required_header>
  <id_info>
    <org_study_id>CRUK-PH2/049</org_study_id>
    <secondary_id>CDR0000415352</secondary_id>
    <secondary_id>NCI-6500</secondary_id>
    <nct_id>NCT00104897</nct_id>
  </id_info>
  <brief_title>17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma</brief_title>
  <official_title>A Phase II Trial to Assess the Activity of 17-allylamino, 17-demethoxygeldanamycin (17-AAG) in Patients With Metastatic (M1, M1b &amp; M1c) Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well 17-N-allylamino-17-demethoxygeldanamycin&#xD;
      works in treating patients with metastatic malignant melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the antitumor activity of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) in&#xD;
           patients with metastatic malignant melanoma.&#xD;
&#xD;
        -  Determine the progression-free rate in patients treated with this drug.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity profile of this drug in these patients.&#xD;
&#xD;
        -  Determine the duration of response in patients treated with this drug.&#xD;
&#xD;
        -  Determine the survival of patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, open-label, multicenter study.&#xD;
&#xD;
      Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1 hour on days 1,&#xD;
      8, 15, and 22. Treatment repeats every 28 days for 3 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. After 3 courses of treatment, disease response is&#xD;
      assessed. Patients with stable or responding disease receive additional courses of treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 28 days and then every 3 months&#xD;
      thereafter.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-25 patients will be accrued for this study within 12-18&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease stabilization at 6 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile as measured by NCI CTCAE version 3</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effects as measured by western blot, magnetic resonance spectroscopy, and enzyme-linked immunosorbent assay (ELISA) during course 1</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-RAF and RAS mutation status at baseline</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tanespimycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed malignant melanoma&#xD;
&#xD;
               -  Metastatic (M1a, M1b, or M1c) disease&#xD;
&#xD;
          -  Measurable disease by clinical exam, x-ray, CT scan, or MRI&#xD;
&#xD;
          -  Must have documented disease progression at 2 time points separated by ≥ 6 months&#xD;
&#xD;
               -  Pre-existing visceral lesions or the appearance of new visceral lesions allowed&#xD;
&#xD;
               -  New skin disease amenable to surgery not allowed&#xD;
&#xD;
          -  No primary brain tumors or brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  ALT and AST ≤ 1.5 times upper limit of normal&#xD;
&#xD;
          -  No chronic liver disease&#xD;
&#xD;
          -  No known hepatitis B or C positivity&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 130 mmol/L OR&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No transient ischemic attack&#xD;
&#xD;
          -  No stroke or peripheral vascular disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception for 4 weeks before, during, and for&#xD;
             6 months after study participation&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No diabetes mellitus with evidence of severe peripheral vascular disease or ulcers&#xD;
&#xD;
          -  No history of allergy to eggs&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No other malignancy except adequately treated cone-biopsied carcinoma in situ of the&#xD;
             cervix or basal cell or squamous cell skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 4 weeks since prior endocrine therapy&#xD;
&#xD;
          -  Concurrent steroids allowed provided they are given at the lowest possible maintenance&#xD;
             dose&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy unless administered for palliative care&#xD;
&#xD;
          -  Concurrent radiotherapy allowed provided it is administered as a single fraction for&#xD;
             bone pain OR as indicated for palliative care&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
               -  Alopecia allowed&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation with warfarin&#xD;
&#xD;
               -  Concurrent prophylactic warfarin for central line maintenance allowed provided&#xD;
                  INR is checked regularly until stable&#xD;
&#xD;
               -  Concurrent low-molecular weight heparin allowed&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Eisen</last_name>
    <role>Study Chair</role>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S, Owen K, Asad Y, Raynaud F, Walton M, Judson I, Workman P, Eisen T. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs. 2012 Feb;30(1):341-9. doi: 10.1007/s10637-010-9493-4. Epub 2010 Aug 5.</citation>
    <PMID>20683637</PMID>
  </results_reference>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>March 3, 2005</study_first_submitted>
  <study_first_submitted_qc>March 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2005</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

